SARS-CoV-2 under an elimination strategy in Hong Kong.
Journal
medRxiv : the preprint server for health sciences
Titre abrégé: medRxiv
Pays: United States
ID NLM: 101767986
Informations de publication
Date de publication:
23 Jun 2021
23 Jun 2021
Historique:
entrez:
30
6
2021
pubmed:
1
7
2021
medline:
1
7
2021
Statut:
epublish
Résumé
Hong Kong utilized an elimination strategy with intermittent use of public health and social measures and increasingly stringent travel regulations to control SARS-CoV-2 transmission. By analyzing >1700 genome sequences representing 17% of confirmed cases from 23-January-2020 to 26-January-2021, we reveal the effects of fluctuating control measures on the evolution and epidemiology of SARS-CoV-2 lineages in Hong Kong. Despite numerous importations, only three introductions were responsible for 90% of locally-acquired cases, two of which circulated cryptically for weeks while less stringent measures were in place. We found that SARS-CoV-2 within-host diversity was most similar among transmission pairs and epidemiological clusters due to a strong transmission bottleneck through which similar genetic background generates similar within-host diversity. Out of the 170 detected introductions of SARS-CoV-2 in Hong Kong during 2020, three introductions caused 90% of community cases.
Identifiants
pubmed: 34189537
doi: 10.1101/2021.06.19.21259169
pmc: PMC8240692
pii:
doi:
Types de publication
Preprint
Langues
eng
Subventions
Organisme : NIAID NIH HHS
ID : 75N93021C00016
Pays : United States
Organisme : NIAID NIH HHS
ID : HHSN272201400006C
Pays : United States
Organisme : NIAID NIH HHS
ID : U01 AI151810
Pays : United States
Commentaires et corrections
Type : UpdateIn
Références
Lancet Public Health. 2020 May;5(5):e279-e288
pubmed: 32311320
Science. 2020 May 8;368(6491):
pubmed: 32234805
J Virol. 2017 Jun 26;91(14):
pubmed: 28468874
Nat Med. 2020 Nov;26(11):1714-1719
pubmed: 32943787
Nat Hum Behav. 2021 Apr;5(4):529-538
pubmed: 33686204
Lancet Infect Dis. 2020 Jun;20(6):669-677
pubmed: 32240634
PLoS Pathog. 2021 Feb 26;17(2):e1009373
pubmed: 33635912
Lancet Infect Dis. 2020 May;20(5):533-534
pubmed: 32087114
Proc Natl Acad Sci U S A. 2013 Jan 2;110(1):228-33
pubmed: 23248286
Euro Surveill. 2021 Jan;26(1):
pubmed: 33413740
Science. 2021 Apr 16;372(6539):
pubmed: 33688063
BMJ. 2020 Dec 22;371:m4907
pubmed: 33561814
Nat Med. 2020 Apr;26(4):506-510
pubmed: 32284616
Euro Surveill. 2020 Mar;25(12):
pubmed: 32234121
N Engl J Med. 2020 Apr 30;382(18):e45
pubmed: 32294373
Nat Microbiol. 2020 Nov;5(11):1403-1407
pubmed: 32669681
Nature. 2020 Mar;579(7798):265-269
pubmed: 32015508
Euro Surveill. 2020 Mar;25(10):
pubmed: 32183930